Paper18400400
Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin.
Crofford LJ and 6 others. Pain, 2008. Cited by 182 papers, by iCite.
Cite this record
ConductScience Library. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Papers, record 18400400. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18400400
- Disease
- fibromyalgia103 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Clinical Protocols | Major topic |
| Clinical Trials as Topic | Major topic |
| Fibromyalgia | Major topic |
| Outcome Assessment, Health Care | Major topic |
| Placebo Effect | Major topic |
| gamma-Aminobutyric Acid | Major topic |
| Adrenergic Uptake Inhibitors | |
| Analgesics | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Longitudinal Studies | |
| Male | |
| Middle Aged | |
| Pregabalin | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01397006 | Fibromyalgia of Less Than One Year Duration. Study of Pregabalin | Results |
Source ClinicalTrials.gov
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 18384959 | Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors. | https://conductscience.org/library/papers/18384959 | PubMed |
| Comment in | 18684565 | Determining long-term efficacy for treatment of chronic pain in fibromyalgia patients. | https://conductscience.org/library/papers/18684565 | PubMed |
| Comment in | 18852724 | Duloxetine and pregabalin: safe and effective for the long-term treatment of fibromyalgia? | https://conductscience.org/library/papers/18852724 | PubMed |
Cited by68
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 182 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42498694 | Gabapentinoids-duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting. | Br J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42498694 | PubMed |
| 42097637 | Impact of treatment duration on the effectiveness of opioid analgesia: a systematic review and meta-analysis. | Br J Gen Pract | 2026 | https://conductscience.org/library/papers/42097637 | PubMed |
| 40084994 | Treatments for enhancing sleep quality in fibromyalgia: a systematic review and meta-analysis. | Rheumatology (Oxford) | 2025 | https://conductscience.org/library/papers/40084994 | PubMed |
| 39516528 | Transcutaneous electrical nerve stimulation for fibromyalgia-like syndrome in patients with Long-COVID: a pilot randomized clinical trial. | Sci Rep | 2024 | https://conductscience.org/library/papers/39516528 | PubMed |
| 38131736 | Assessing Ethnic Minority Representation in Fibromyalgia Clinical Trials: A Systematic Review of Recruitment Demographics. | Int J Environ Res Public Health | 2023 | https://conductscience.org/library/papers/38131736 | PubMed |
| 37127914 | Emerging treatment for Sjögren's disease: a review of recent phase II and III trials. | Expert Opin Emerg Drugs | 2023 | https://conductscience.org/library/papers/37127914 | PubMed |
| 36529848 | Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval. | Drugs | 2023 | https://conductscience.org/library/papers/36529848 | PubMed |
| 35840702 | Pregabalin administration in patients with fibromyalgia: a Bayesian network meta-analysis. | Sci Rep | 2022 | https://conductscience.org/library/papers/35840702 | PubMed |
| 35210848 | Study Design Characteristics and Endpoints for Enriched Enrollment Randomized Withdrawal Trials for Chronic Pain Patients: A Systematic Review. | J Pain Res | 2022 | https://conductscience.org/library/papers/35210848 | PubMed |
| 32669869 | Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia. | J Pain Res | 2020 | https://conductscience.org/library/papers/32669869 | PubMed |
| 29623147 | Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway. | Pain Res Manag | 2018 | https://conductscience.org/library/papers/29623147 | PubMed |
| 28778847 | Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid - Pregabalin Combination for the Treatment of Fibromyalgia Pain. | JMIR Res Protoc | 2017 | https://conductscience.org/library/papers/28778847 | PubMed |
| 28383710 | The MOBILE Study-A Phase IIa Enriched Enrollment Randomized Withdrawal Trial to Assess the Analgesic Efficacy and Safety of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Patients with Peripheral Neuropathic Pain. | Pain Med | 2017 | https://conductscience.org/library/papers/28383710 | PubMed |
| 27790003 | Management strategies for fibromyalgia. | Open Access Rheumatol | 2011 | https://conductscience.org/library/papers/27790003 | PubMed |
| 27789991 | Advances in diagnostic and treatment options in patients with fibromyalgia syndrome. | Open Access Rheumatol | 2009 | https://conductscience.org/library/papers/27789991 | PubMed |
| 27684492 | Pregabalin for pain in fibromyalgia in adults. | Cochrane Database Syst Rev | 2016 | https://conductscience.org/library/papers/27684492 | PubMed |
| 27107994 | An overview of treatment approaches for chronic pain management. | Rheumatol Int | 2017 | https://conductscience.org/library/papers/27107994 | PubMed |
| 26937205 | Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia. | Drug Healthc Patient Saf | 2016 | https://conductscience.org/library/papers/26937205 | PubMed |
| 26922414 | Fibromyalgia Pathogenesis and Treatment Options Update. | Curr Pain Headache Rep | 2016 | https://conductscience.org/library/papers/26922414 | PubMed |
| 26112278 | Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program. | Pediatr Rheumatol Online J | 2015 | https://conductscience.org/library/papers/26112278 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| PREGABALIN | CHEMBL1059 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1059 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/18400400
GET https://conductscience.org/api/papers/v1/18400400/cited_by?page=2